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Problems Associated with Community-Based Parenteral
Anti-Infective Therapy with Intravenous Ganciclovir for
Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic
Stem Cell Transplant Recipients
S. Mossad1,∗, N. Shrestha2, S. Rehm2, R. Avery2, B. Bolwell 2
1 Cleveland Clinic Foundation, Cleveland, OH, USA
2 Cleveland Clinic, Cleveland, OH, USA
Background: Our center utilized Cytomegalovirus (CMV)
prophylaxis with intravenous ganciclovir (IV GCV) in allo-
geneic hematopoietic stem cell transplant (allo HSCT)
recipients starting from engraftment to day +100. Most
of this regimen was administered as communitybased par-
enteral anti-infective therapy (CoPAT). Surveillance CMV
DNA detection by hybrid capture assay was done weekly
through day +100 and at varying intervals thereafter.
Methods: Retrospective review of the CoPAT database
and electronic medical records to evaluate adherence to this
protocol. Events were followed for 6 months from HSCT.
Results: 66 patients underwent allo HSCT from 5/07 to
6/08. Demographics were similar in patients who received
any prophylactic IV GCV (21 [32%]) and those who did not
(45 [68%]. 36 patients did not receive CoPAT for appropri-
ate reasons: CMV IgG donor negative & recipient negative
(19), delayed engraftment (5), relapse of underlying disease
(5), death within 100 days of HSCT (5), and refractory dis-
ease (2). Protocol deviation occurred in 23 patients (35%): IV
GCV was not started due to physician or patient choice (5),
was started appropriately, but stopped before D +100 due
to physician or patient choice (4), was started for treat-
ment of CMV viremia in a patient who should have been
on prophylactic IV GCV before that point in time (8), and
replacement of prophylactic IV GCV with oral valganciclovir
(6). Other reasons for early discontinuation of prophylactic
IV GCV before D +100 were leucopenia (6) and renal insufﬁ-
ciency (2). Median time from HSCT to starting CoPAT was 41
days. Median CoPAT duration was 45 days. Of the 30 appro-
priate candidates for prophylaxis, only 3 (10%) received the
complete prophylaxis course from engraftment through day
+100. In this nonrandomized study, the incidence of CMV
viremia, peak viral load (VL) and graftversus-host disease
(GVHD) were not signiﬁcantly different between prophy-
laxed, partially prophylaxed, and unprophylaxed groups.
Conclusion: In practice it proved to be difﬁcult to admin-
ister and complete the IV GCV prophylaxis course. Reasons
for this included delayed engraftment, relapsed or refrac-
tory underlying diseases, physician or patient individual
choices, leucopenia, and renal insufﬁciency. This study illus-
trates the importance of assessing prophylaxis strategies in
the context of actual clinical care. Valganciclovir; the L-valyl
ester of GCV is 60% orally bioavailable; representing a more
convenient and effective preventive alternative. Thus, in
1/09 we changed our CMV preventive strategy from universal
prophylaxis to preemptive therapy with valganciclovir.
doi:10.1016/j.ijid.2010.02.645
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description of the pathogenesis associated with piri-
al virus (an arenavirus) infection in the Syrian golden
amster
. Stammen ∗, J. Garver, S. Sarrazine, E. Vela
Battelle, Columbus, OH, USA
Background: Arenaviruses are rodent-borne agents and
ome are capable of causing hemorrhagic fever in humans.
hese viruses cause acute or persistent infection in a
iverse range of animals. Research involving arenaviruses
hat induce hemorrhagic fever is normally performed in
BSL-4 laboratory environment. However, BSL-2/3 are-
aviruses that cause hemorrhagic fever in animals may be
sed as a surrogate model system to screen potential vac-
ines and/or therapeutics. Pirital virus (PIRV) is a BSL-3 New
orld arenavirus that induces hemorrhagic fever manifesta-
ions in the Syrian golden hamster model. This model can be
tilized to screen and test vaccines and therapeutics.
Methods: Female Syrian golden implanted with teleme-
ry units measuring temperature and activity were followed
or 14 days post-challenge. Clinical signs of disease were
onitored. Viral titers in tissues, viremia, clinical chemistry,
ematology, and coagulation parameters and analyzed.
Results: Intraperitoneal infection of female Syrian golden
amsters with PIRV led to a speciﬁc disease progression
nvolving fever, loss of weight, lethargy, petechial rashes,
uddled posture, rufﬂed fur, epistaxis, and orbital hemor-
haging. Animals surviving to the later stages of disease
xhibited whole body tremors, loss of balance, shaking, hind
imb paralysis, and rectal hemorrhaging. PIRV infection in
amsters results in 100%mortality in 6-8 days after challenge
nd analyses of tissues resulted in measureable viremia and
iral titers in the adrenals, lymph nodes, intestines, kidney,
iver, and brain. Changes in clinical chemistry parameters
uggest liver and kidney damage while coagulation param-
ters demonstrate a disruption of coagulation and clotting.
ematology data demonstrate an increase in white blood
ell (WBC) and an increase or stabilization of thrombocytic
ounts.
Conclusion: In all, this has led to a description of a
emorrhagic fever model to study arenavirus hemorrhagic
ever pathogenesis and can be used as a cost effective,
ime-efﬁcient BSL-3 surrogate to screen various antiviral
herapeutics and/or vaccine strategies.
oi:10.1016/j.ijid.2010.02.646
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odiﬁcation of the type I interferon and proinﬂammatory
ytokine responses by enterovirus 71
.-P. Lee1,∗, S.-W. Huang1, Y.-F. Wang2, C.-K. Yu1
National Cheng Kung University, Tainan City, Taiwan, R.O.C
National Health Research Institute, Tainan City, Taiwan,
.O.CBackground: Enterovirus 71 (EV71) is a neutropic virus
argeting the brain stem that may result in severe seque-
ae including paralysis and pulmonary edema (PE). Type
interferons (IFNs) represent an essential innate defense
